Freedman R S, Saul P B, Edwards C L, Jolles C J, Gershenson D M, Jones L A, Atkinson E N, Dana W J
Cancer Treat Rep. 1986 Mar;70(3):369-73.
Patients with ovarian carcinoma refractory to chemotherapy received a sequential combination of ethinyl estradiol and medroxyprogesterone acetate in two dose regimens. There was no difference in therapeutic activity of the two dose regimens. Of 65 patients, nine (14%) responded to treatment and 13 (20%) had stable disease. Vascular complications occurred in three patients; hemiplegia developed in one of those. Nine patients had significant nausea and vomiting, and one experienced severe depression that required treatment withdrawal. The sequential and combined use of ethinyl estradiol and medroxyprogesterone acetate may provide an alternative treatment for certain patients with ovarian carcinoma that does not respond to optimum chemotherapy. Additional studies are required to determine if synergism exists between this treatment and other modalities of therapy. Further investigation is required into the vascular disorders that complicate therapy to determine whether appropriate preventive measures are possible.
对化疗难治的卵巢癌患者接受了两种剂量方案的炔雌醇和醋酸甲羟孕酮序贯联合治疗。两种剂量方案的治疗活性没有差异。65例患者中，9例（14%）对治疗有反应，13例（20%）病情稳定。3例患者出现血管并发症；其中1例发生偏瘫。9例患者有明显的恶心和呕吐，1例出现严重抑郁，需要停止治疗。炔雌醇和醋酸甲羟孕酮的序贯联合使用可能为某些对最佳化疗无反应的卵巢癌患者提供一种替代治疗方法。需要进一步研究以确定这种治疗与其他治疗方式之间是否存在协同作用。需要对使治疗复杂化的血管疾病进行进一步调查，以确定是否有可能采取适当的预防措施。
